-Laronidase is indicated for the treatment of patients with mucopolysaccharidosis I (MPS I), a lysosomal storage disorder characterized by the deficiency of alpha-L-iduronidase. -It is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. It has been shown to improve pulmonary function and walking capacity.
-The dosage of Laronidase is individualized based on the patient's weight. It is administered intravenously over a specified period, typically on a weekly basis. The infusion rate and duration may vary, and healthcare professionals should determine the appropriate dosage for each patient. -IV infusion; The recommended dosage regimen is 0.58 mg/kg of body weight administered once weekly as an intravenous (IV) infusion.
Laronidase is contraindicated in individuals with a known hypersensitivity to the active substance or any of the excipients in the formulation.
-Patients should be monitored for hypersensitivity reactions during and after infusion. -Caution is advised in patients with compromised respiratory function. -Regular assessments of respiratory and cardiac function are recommended. Paediatric: Safety and efficacy in 6 month to 18 year old is similar to adults Pregnancy: Category B Lactation: It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when it is administered to a nursing woman. Elderly: Data not sufficient
-Common side effects may include: Hypersensitivity reactions (fever, chills, rash) Headache Nausea Vomiting Serious side effects are rare but may include anaphylaxis. Patients should seek immediate medical attention if they experience severe allergic reactions. -Infusion reaction, Thrombocytopenia, Corneal opacity, Chest pain, Face edema, Gravitational edema, Injection site pain, Injection site reaction , Hyperbilirubinemia, Abscess, Upper respiratory tract infection, Hyperreflexia, Paresthesia, Rash, Hypotension, Poor venous access.
There are no known drug interactions with Laronidase. However, patients should inform their healthcare providers about all medications, including over-the-counter and herbal supplements, to ensure safe co-administration.